Roche Holding AG

Roche Holding AG’s 2026 AGM highlights Swiss R&D focus, new equity structure, dividend boost, and a clear plan to tackle patent cliffs while targeting M&A to stay pharma‑market‑leading.

Roche’s market dip amid geopolitical tension masks strong clinical progress—phase‑III ALLEGORY shows 46% SLE remission, while phase‑II Petrelintide cuts BMI by 2.8 kg/m².

Roche’s latest regulatory moves—dropping Enspryng and winning FDA NDA acceptance for a new breast‑cancer drug and a giredestrant combo—signal a sharp focus on high‑impact oncology therapies and a promise of improved outcomes for hormone‑positive bre…

Roche’s FDA‑approved breast‑cancer therapy RO‑101 shows a 12.6‑month median PFS, while its ER‑OAR+everolimus combo promises 9.2‑month PFS and higher response rates—2026‑decision outlook revealed.

Roche’s new oral MS drug, Fenebrutinib, cuts disability progression and preserves arm function with a safety profile similar to Ocrevus, while the company supports early‑career researchers and maintains a stable market outlook.

Roche Holding AG’s AI‑driven R&D, diversified pipeline and emerging market growth face patent cliffs, regulatory shifts and investor uncertainty – a nuanced analysis for informed investors.

Goldman Sachs lifts Roche Holding to neutral, citing stronger diagnostics-driven pricing and solid balance sheet amid looming patent cliffs – a fresh outlook for investors.

Roche Holding AG’s bold obesity and YL201 moves spotlight a rare diagnostics‑therapeutics synergy—explore how this could reshape its revenue and risk profile.

Roche’s share rise after U.S. drug‑price settlement shows investors believe tariff exemptions will offset revenue loss while keeping Genentech biologics safe, effective, and more affordable.

Roche’s share hits a 12‑month high after JPMorgan upgrades it to neutral—backed by new EU approval for Gazyva in lupus nephritis and a promising Lunsumio/Lenalidomide combo for lymphoma, signaling strong regulatory momentum and investment confidence.